Q-omics provides the consensus-scored HCN3 profile across patient tissues and cancer cell-line models. HCN3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HCN3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, HCN3 RNA expression shows 19,701 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BLCA, and UVM as cancer lineages where HCN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HCN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HCN3 survival associations across molecular data types. HCN3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HCN3 RNA expression–survival associations across cancer types. High HCN3 expression shows unfavorable associations in ACC and KICH, but favorable associations in UVM, LGG, BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HCN3 RNA expression.
This table summarizes HCN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HCN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HCN3 shows higher tumor expression in BLCA, LUAD, STAD, COAD, LUSC and BRCA. The BLCA box plot shows higher HCN3 RNA expression in tumor versus normal tissue (log2 FC = +1.343, t-test p < 0.001).
This table shows molecular features associated with HCN3 in patient tissues and cancer cell lines. In patient samples, HCN3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HCN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
